U. S.  Securities and Exchange Commission
                       Washington, D.C. 20549

           Form 10-QSB -- Quarterly or Transitional Report
           (Added by 34-30968, eff.  8/13/93, as amended)


(Mark One)
[ X ]  Quarterly Report Under Section 13 or 15(d) of the Securities 
       Exchange Act of 1934  

For the quarterly period ended June 30, 1997

[   ]   Transition Report Under Section 13 or 15(d) of the Securities 
        Exchange  Act of 1934   

For the transition period from	to	________________ to _________________

Commission file number 0-17032

                        PROTEIN DATABASES, INC.		
-----------------------------------------------------------------
(Exact name of small business issuer as specified in its charter)   

Delaware                             13-3186604
---------------------------------    -----------------
(State or other jurisdiction of      (I.R.S. Employer 
 incorporation or organization)      Identification No.)

405 Oakwood Road, Huntington Station, New York    11746
----------------------------------------------    ----------
(Address of principle executive offices)          (Zip Code) 

(516) 673-3939 
-------------------------
Issuer's telephone number
 
(Former name, former address and former fiscal year, 
 if changed since last report)
-----------------------------------------------------
Check whether the issuer (1) filed all reports required to be filed by 
Section 13 or 15(d) of the Exchange Act during the past 12 months 
(or for such shorter period that the registrant was required to file 
such reports), and (2) has been subject to such filing requirements for 
the past 90 days. Yes   x   .  No___.

State the number of shares outstanding of each of the issuer's classes 
of common equity, as of the latest practicable date.

Class                                  Outstanding at June 30, 1997
---------------------------            -----------------------------
Common Stock $.01 par value            1,459,724

<PAGE>

                            PROTEIN DATABASES, INC.

                                BALANCE SHEET

                                June 30,1997
                                ( UNAUDITED )


                                   ASSETS


CURRENT ASSETS:

Cash and cash equivalents          $145,274
Accounts receivable                 139,277 
Inventory                            28,572
Prepaid expenses                      8,672
                                   --------
Total current assets                321,795
                                   --------				

PROPERTY AND EQUIPMENT-NET          154,365
                                   --------
            
OTHER ASSETS                          9,020
                                   --------

TOTAL                              $485,180
                                   ========


                    LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
  Accounts payable                  $87,967
  Accrued expenses                   58,064 
  Unearned revenue                   24,520
                                   -------- 
  Total current liabilities         170,551
                                   --------

STOCKHOLDERS' EQUITY:
  Common stock                       14,597 
  Additional paid-in capital      8,519,636 
  Accumulated deficit            (8,219,604)
                                 ----------
Stockholders' Equity                314,629
                                 ----------

TOTAL                              $485,180
                                 ==========

<PAGE>

                        PROTEIN DATABASES, INC.

                  CONDENSED STATEMENTS OF OPERATIONS
                            ( UNAUDITED )

                          For the Three Months     For the Six Months
                             Ended June 30,          Ended June 30,
                          --------------------     ------------------
                          1997       1996           1997        1996
                          ----       ----           ----        ----

Revenues              $245,430   $547,436       $780,382    $909,349  
                      --------   --------       --------    -------- 
Expenses
  Cost of sales        142,374    173,127        236,652     349,089
  General 
    and administrative 140,980    175,887        294,853     334,081
  Marketing 
    and sales          132,056    187,725        268,346     388,351
  Research 
    and development     83,293    138,992        184,474     289,715
                       -------    -------        -------     -------
  Total expenses       498,703    675,731        984,325   1,361,236  
                       -------    -------      ---------   ---------

Net (loss)           $(253,273) $(128,295)     $(203,943)  $(451,887)
                      ========   ========      =========    ========

Net income (loss) 
  per common share       $(.17)     $(.09)        $(.14)       $(.31)
                      ========   ========      ========     ========

Weighted average number of 
  shares used in computing
    earnings per share

                     1,459,724  1,459,724     1,459,724    1,459,724
                     =========  =========     =========    =========

<PAGE>

                         PROTEIN DATABASES, INC.

                    CONDENSED STATEMENTS OF CASH FLOWS
                              ( UNAUDITED )

                                      For the Six Months
                                       Ended June 30,
                                     --------------------
                                     1997            1996
                                     ----            ----

Cash flow from operations:
  Net income (loss)             $(203,943)      ($451,887)
  Adjustments to reconcile 
    net income to net cash 
    provided by 
    (used in) operations:

  Depreciation and amortization	   48,000          48,000
  Changes in operating assets 
  and liabilities:

  Accounts receivable             224,568          23,878
  Inventory                        30,911          19,930 
  Prepaid expenses
    and deposits                    2,641          (4,048)
  Accounts payable and 
    accrued expenses              (78,761)        (77,769)
  Unearned revenue                (18,066)          4,641
                                 --------        --------
  Net cash provided by operations   5,350        (437,255)
                                 ========        ========

Cash flows from (investments in) 
  sale of property and 
     equipment, net                20,572         (60,867)
                                 --------        --------

Increase (decrease) in cash    
  and cash equivalents             25,922        (498,122)
                                 --------        --------

Cash and cash equivalents, 
  beginning of period            119,352          778,718
                                --------         --------
Cash and cash equivalents, 
  end of period                 $145,274         $280,596
                                ========         ========

<PAGE>
                                       						 ( Unaudited )
 
                      PROTEIN DATABASES, INC.	

                    NOTES TO FINANCIAL STATEMENTS

                          JUNE 30, 1997

NOTE 1 - GENERAL:

The accompanying unaudited financial statements include all adjustments, 
consisting of normal recurring accruals, which are, in the opinion of 
management, necessary for a fair statement of the results of the interim 
periods.  The statements have been prepared in accordance with the 
requirements for quarterly reports on Form 10-QSB and, therefore, do not 
include all disclosures or financial details required by generally 
accepted accounting principles.  These condensed financial statements 
should be read in conjunction with the financial statements and the notes
thereto included in the Company's Annual Report on Form 10-KSB for the 
year ended December 31, 1996.

The results of operations for the interim periods are not necessarily 
indicative of results to be expected for a full year's operations.

<PAGE>

                         PROTEIN DATABASES, INC.
                         -----------------------
           Management's Discussion and Analysis of Operations
           --------------------------------------------------

Liquidity and Capital Resources

The Company's present liquidity position is critical.  During the year ended 
December 31, 1996, the Company had a net loss from operations of $811,323.
As of June 30, 1997, the Company's total current assets were $321,795 
(including cash of $145,274) and its total liabilities were $170,551
(see accompanying Balance Sheet).

On July 21, 1997, the Company announced that it had entered into a 
an agreement to sell all of its intellectual property, fixed assets 
and property, plant and equipment for $1 million to Bio-Rad Laboratories, 
Inc. of Hercules, California.  The transaction is subject to the approval of 
the Company's shareholders at a meeting expected to be held in the fall of 
1997 and certain other conditions.  Shareholders will also be asked at the 
meeting to approve the dissolution and liquidation of the Company following
consummation of the sale to Bio-Rad.  In contemplation of the Bio-Rad 
transaction, the Company has ceased all development and marketing activities.

As a result of the limited amount of funds currently available to finance
the Company's operations, the report of the Company's independent 
Certified Public Accountants on the Financial Statements as of December 
31, 1996 contains an explanatory paragraph indicating that there is 
substantial doubt about the Company's ability to continue as a going 
concern.

The Company had no material commitments for capital equipment additions
at June 30, 1997.

Revenues

The Company generates revenues primarily by selling software systems
and,to a lesser extent, from contract research and development, royalties
and other income sources.  


<PAGE>

                      PROTEIN DATABASES, INC.
  --------------------------------------------------------------
  Management's Discussion and Analysis of Operations (Continued)

1997's revenues include approximately $280,000 of revenue from Toyobo Co. Ltd.,
("Toyobo"), the exclusive distributor of the Company's products in Japan, 
which amount essentially constitutes all of Toyobo's purchase commitments 
from the Company for 1997.

Expenses

The Company's cost of sales decreased in the three months and six months ended
June 30, 1997 from the comparable periods of the prior year as a result of 
lower costs for supplies and equipment and fewer employees in the department.

The Company's sales and marketing expenses decreased in the three months
and six months ended June 30, 1997 from the comparable periods in the prior 
year principally as a result of lower salary and related expenses, due to 
two less employees, and lower costs for supplies, travel and promotional
expenses.

The decrease in the Company's research and development expenses in the
three months and six months ended June 30, 1997 from the comparable periods 
in the prior year was primarily attributable to fewer employees in the 
department and lower costs for supplies and travel expenses.  

<PAGE>

Part II - Other Information

Item 6.	Exhibits and Reports on Form 8-K

        ( a ) 	 Exhibits: EX-27.

        ( b )   Reports on Form 8-K:  There were no reports on
                Form 8-K filed by the Company during the three months
                ended June 30, 1997.

<PAGE>

Signatures


In accordance with the requirements of the Securities and Exchange Act of
1934, the registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.




 
                                     Protein Databases, Inc.			
                                     -----------------------
                                         (Registrant)



Dated July 31, 1997                   S/Stephen H. Blose
                                      Stephen H. Blose
                                      Director, President and
                                      Chief Executive Officer
                                      (Principal Financial and
                                       Accounting Officer)